Common prostate cancer medications may be less safe than previously thought

Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.

10:05 AM

Author | Mary Clare Fischer

Magnifying-Glass-Pills-Blue-Background
Getty Images

Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were only receiving hormone therapy, Michigan Medicine researchers found.

Patients taking abiraterone had 1.77 times the risk of being admitted to the emergency room or the hospital due to diabetes, hypertension or heart disease compared to those who were only on hormone therapy. Those receiving enzalutamide were at 1.22 times the risk of these issues.

Compared to patients not receiving abiraterone, those taking abiraterone were also more likely to need an outpatient visit with their physician related to at least one of these health conditions. That was not the case if the man was taking enzalutamide.

Abiraterone and enzalutamide were both found to be relatively safe in clinical trials, but concerns that the population of patients who participated in the trials was different than those in real-life settings prompted the researchers to take another look at the effects of the drugs.

For instance, this research exclusively analyzed patients with Medicare health insurance, and the majority of men studied were significantly older than those in the drugs' clinical trials.

"Patients enrolled in clinical trials tend to be highly selected and often times do not reflect the patient population in day-to-day practice," said Lillian Y. Lai, M.D., M.S., a National Institutes of Health T32 Urologic Oncology Research Fellow at Michigan Medicine and the first author of the study. "Trial participants also undergo stringent safety evaluations that some of our patients do not have access to. By studying adverse events in real-life settings, we can better understand the risks of these life-prolonging cancer treatments and help clinicians and patients make informed decisions regarding treatment."

Since metabolic and cardiovascular conditions tend to be under the purview of primary care providers, Lai and her fellow authors recommend team-based care that involves PCPs for patients with advanced prostate cancer as a way to manage these higher risks.

"With continued expansion of the indications for abiraterone and enzalutamide to earlier stages of the disease, increasing numbers of men will be receiving these therapies for longer periods of time," Lai said. "This will potentially amplify the scope of men affected and increase the magnitude of the risks of adverse events, making careful attention to management of these issues crucial."

Other authors include Mary K. Oerline, M.S.; Megan E.V. Caram, M.D., M.S.; Phoebe A. Tsao, M.D.; Samuel R. Kaufman, M.A.; Brent K. Hollenbeck, M.D., M.S.; and Vahakn B. Shahinian, M.D., M.S.

Paper cited: "Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer," Journal of the National Cancer Institute. DOI: 10.1093/jnci/djac081


More Articles About: Lab Notes Patient Safety Prostate Cancer Cancer: Help, Diagnosis & Treatment Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories frozen dial with ice on it with red dial
Health Lab
Enzyme identified as new therapeutic target for “cold” tumors
A study identifies an enzyme as a new therapeutic target for “cold” tumors.
three friends standing outside rogel cancer center building with big white ribbons
Health Lab
A lung cancer survivor shaping lung cancer advocacy
One woman's unexpected lung cancer diagnosis leads her to help many who aren't aware they're at risk of the disease.
man and woman jogging outside with greenery behind them and fence on sidewalk
Health Lab
Exercise and physical activity help with cancer recovery and prevention
When it comes to living well and preventing cancer, scientists long ago established that exercise and physical activity are key. But some cancer survivors wonder which activities are best for maximizing health benefits. An assistant professor of applied exercise science at the University of Michigan School of Kinesiology talks more.
surgeon close up operating in bright lighted room
Health Lab
In 10 seconds, AI model detects cancerous brain tumor often missed during surgery
Researchers have developed an AI powered model that — in 10 seconds — can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a study published in Nature suggests.
close up of orange and purple squiggle-looking cells merging and a little green in the middle
Health Lab
Researchers find metabolic mechanism that blocks immune response, immunotherapy in cancer
New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.
graphic drawing of woman falling and everything is pink and falling and floating with her like dna strands, cars, people, medicine, ID, blood vessels and cells
Health Lab
Why are more young people being diagnosed with cancer?
An article discusses causes of early-onset cancer and ways to reduce your risk.